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ABSTRACT: This research examines the neurological similarities between schizophrenia and major depressive disorder 
with psychotic features to compare the manifestations of psychosis in each disorder. Both disorders often involve 
symptoms of psychosis, although the disorders overall are very different. We hypothesize that the neurological 
similarities between schizophrenia and major depressive disorder with psychotic features will provide researchers with 
the strategies needed to develop a treatment for psychotic symptoms. In order to test this hypothesis, five related 
studies were gathered for each disorder, and three studies were gathered for psychosis. These studies were then analyzed 
to pinpoint any similarities among factors for psychosis, and this analysis allowed for the determination of whether the 
hypothesis would be rejected. The results indicated that many of the similarities between the two disorders cannot be 
verified because of the lack of substantial research.
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BACKGROUND
Symptoms, Epidemiology, and Diagnosis
Schizophrenia
Patients with schizophrenia experience positive and 
negative symptoms. Positive symptoms are perceptions 
that are not normally present in the general population, 
such as hallucinations and delusions. Negative symptoms 
occur when perceptions that are normally present in the 
general population are absent. These symptoms include 
reduced emotional expression (i.e., constricted/flat 
affect) and reduced motivation (i.e., avolition) [11]. 
Causes for this disorder are still being researched, although 
studies have shown that genetic and environmental 
factors may contribute to its development. It is difficult 
to determine whether specific environmental factors 
can lead to the development of schizophrenia or if 
these factors simply co-occur with the disorder. For this 
reason, we can think of environmental factors as potential 
risk factors rather than causes. There are three different 
“levels” of risks: highest-level, intermediate, and lower-
level [14]. Highest-level risk factors appear to have more 
significance compared to intermediate and lower-level 
risks. Intermediate risks involve having had a father over 
the age of fifty-five at the time of birth and having minor 
physical abnormalities [2]. Lower-level environmental 
risk factors include exposure to harmful agents before 
birth, and highest-level risk factors include having an 
affected first-degree relative. 
Additional risk factors include childhood sexual abuse 
and traumatic brain injury. Ongoing use of cannabis in 
early adolescence (prior to age 16) is shown to accelerate 
one's risk of experiencing psychosis [12]. Another factor 
that may increase one’s risk for developing this disorder 
is social withdrawal. To reduce the risk of developing 
schizophrenia, individuals should avoid social isolation 
and seek psychological intervention if initial signs, 
such as behavioral changes and fragmented psychotic 
symptoms, begin to occur [13]. This recommendation 
is especially important if there is a family history of 
schizophrenia, as this is correlated with higher-level risk. 
It is not certain whether a person must be genetically 
predisposed in order to develop the disorder.
To be diagnosed with schizophrenia, patients can undergo 
physical examinations, screenings to rule out conditions 
with similar symptoms, and psychiatric evaluation [7]. 
Individuals should also meet the diagnostic criteria listed 
in the DSM-5.
MDD-PF
MDD-PF, also called psychotic depression, is a subset of 
major depressive disorder in which patients sometimes 
experience psychosis during a depressive episode. 
Symptoms include fatigue, social isolation, difficulty 
concentrating, and insomnia or hypersomnia [15]. 
Symptoms may differ slightly depending on the age 
of the patient. The exact cause is not known, although 
biological changes in the brain, neurochemistry, and 
genetics are thought to play a role. Researchers believe 
that imbalances in the neurotransmitters dopamine 
and glutamate may be present in both MDD-PF and 
schizophrenia, although further testing is required to 
confirm this. Genetic factors play an important role in 
the disorder, as studies have shown that genetic offspring 
are more likely to suffer from MDD-PF. Poor physical 
health and traumatic life events are associated with 
MDD-PF, indicating that environmental factors may 
play a role. 
Environmental factors are limited in cases of MDD-
PF, mainly due to the lack of substantial research. 
Psychosocial factors have been shown to play a role. One’s 
social environment can have an effect on the development 
of psychosis in MDD-PF, as social isolation is generally 
shown to increase risk [8]. Other factors that can lead to 
the development of psychosis mirror the environmental 
risk factors for schizophrenia. Child abuse and maternal 
separation can lead to the development of psychosis in 
susceptible individuals. 
Because depression tends to co-occur with chronic 
diseases, physicians may run lab tests or do physical 
examinations on patients who show symptoms. For 
example, physicians often test for hypothyroidism, 
as an underactive thyroid may cause patients to feel 
depressed and fatigued [16]. It is common for doctors to 
fail to diagnose hypothyroidism due to the presence of 
depressive symptoms, so it is important that a blood test 
is done in order to rule out this possibility. A psychiatric 
evaluation may be used to diagnose the disorder.  
Biological Factors
As with most psychiatric disorders, biological factors 
affect the development and manifestation of both 
disorders. Schizophrenia and MDD-PF are believed to 
12.1: 29-41
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be influenced by both genetics and environmental factors.
Schizophrenia 
Schizophrenia may involve an imbalance in certain 
neurotransmitters, including dopamine, which is 
responsible for motivation and reward, and glutamate, 
the primary excitatory neurotransmitter [4]. 
Neuroimaging can provide information about how the 
disorders relate to differences in the brain structure or 
function and can assist researchers in understanding the 
neurobiology behind each disorder. This information 
aids in the development of treatments and diagnostic 
procedures. An MRI study of monozygotic twins in 
which one was affected by schizophrenia and one 
was not showed that those with schizophrenia have 
larger ventricles. This trend is also true of those who 
are unaffected carriers [4]. Studies have also shown 
that those who suffer from schizophrenia have smaller 
hippocampal volumes. Additionally, schizophrenia is 
structurally characterized by reduced white and gray 
matter. Individuals with schizophrenia may exhibit 
deficiencies in parts of the brain that depend on the 
prefrontal cortex (PFC) [4].
Biological risk factors can start before birth, as minor 
physical anomalies (MPAs) are thought to play a role in 
developmental disorders. MPAs have been observed to 
have an increased prevalence in schizophrenic patients. 
Nutritional factors (i.e., low levels of vitamin D) may 
also play a role in the development of psychosis [2]. 
These potential risk factors warrant further research to 
determine whether they cause psychotic symptoms.  
MDD-PF
MDD-PF has a heritability of approximately 40% [5]. 
This figure is likely due to the molecular genetics and 
pathophysiology of MDD. However, research is fairly 
limited. Based on available pharmacogenetics studies, it is 
thought that MDD-PF is heavily influenced by genetics. 
Linkage studies indicate that there is an overlap between 
specific genetic risks for depression and schizophrenia. 
In a study of patients with MDD, it was discovered that 
the brain derived neurotropic factor (BDNF) val66met 
polymorphism is associated with psychosis [6]. In 
contrast to MDD without psychotic features, additional 
genes were found to be associated with MDD-PF. Some 
of these genes include single nucleotide polymorphisms 
in the dysbindin (DTNBPI) gene, the A allele of the 
444G/A variant in the dopamine beta-hydroxylase 
(DBH) gene, and the active allele of the monoamine 
oxidase A (MAO-A) variable number of tandem repeats 
(VNTR) [6]. 
Postmortem and neuroimaging studies have shown that 
reductions in grey matter and glial density in the PFC 
and hippocampus are characteristic of depression. High 
amounts of cortisol in MDD-PF may be explained by 
decreased hippocampal function, since this can inhibit 
the hypothalamic-pituitary-adrenal (HPA) axis [9]. 
The amygdala is also affected [9]. This disorder is not as 
well-researched as other, more common psychological 
disorders so there are many potential risk factors that 
have not been investigated.
Treatments and Prevention
There is no cure for either schizophrenia or MDD-PF, 
so various treatments are often used. These treatments 
include antipsychotics, antidepressants, electroconvulsive 
therapy, and cognitive behavioral therapy. 
Schizophrenia 
Treatment for schizophrenia commonly involves 
medications and psychosocial therapy. There is no cure so 
many patients continue to receive treatment throughout 
their lives. However, some patients with schizophrenia 
experience spontaneous remission and no longer require 
treatment. Studies show that in cases of schizophrenia 
in which patients have made a full recovery, about 12 
to 22% of these patients experience one single episode 
of schizophrenia [13]. Treatment is often guided by a 
psychiatrist and a treatment team. Hospitalization may 
be necessary in extreme cases. Electroconvulsive therapy 
(ECT) may be considered effective for patients who 
do not respond to drug therapy. Medications typically 
used for drug therapy can be put into two categories: 
first-generation and second-generation antipsychotics 
[7]. Research has shown that second-generation 
antipsychotics may be associated with increased efficacy 
in the treatment of major depressive disorder [32]. 
Patients who use second-generation antipsychotics show 
slight improvements in overall symptoms compared to 
first-generation antipsychotics. Evidence also indicates 
that there may be fewer side effects associated with 
certain second-generation antipsychotics than first-
generation antipsychotics. This trend may be dependent 
on the specific drug used, as some second-generation 
antipsychotics are associated with increased sedation or 
weight gain. 
12.1: 29-41
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Psychosocial therapy includes individual or family 
therapy, social skills training, or vocational rehabilitation. 
As mentioned previously, avoiding social isolation and 
seeking intervention if there are any early signs of 
schizophrenia can aid in prevention. Other methods for 
prevention include developing social skills and learning 
coping mechanisms to deal with negative emotions. 
MDD-PF
There is currently no cure for MDD-PF but there are 
measures to manage the symptoms. These include 
medications, psychotherapy, hospitalization, and brain 
stimulation therapies. Antidepressants in combination 
with antipsychotic medications may help treat the 
disorder, although these medications may not be 
effective until months after a patient begins taking 
them.  Common medications used to treat MDD-PF 
are selective serotonin reuptake inhibitors (SSRIs), 
antidepressants that increase serotonin levels and are 
often used in combination with antipsychotics [17]. 
Psychotherapy involves learning cognitive and 
behavioral skills to alleviate symptoms with a mental 
health professional. If MDD-PF is severe, typically 
if patients begin harming themselves or attempt to 
commit suicide, hospitalization may be necessary. ECT 
is a form of brain stimulation therapy utilized to treat 
MDD-PF. Prevention of the initial onset of MDD 
may be possible. If a person is at risk for depression, 
undergoing cognitive or behavioral therapies may be 
beneficial. However, prevention of depression has not 
been studied extensively and is difficult to prevent due to 
the prominence of genetic factors.
This pathway involves the “exocytotic release of 
serotonin from presynaptic vesicles into the synaptic 
cleft.” This mechanism allows serotonin to interact with 
postsynaptic receptors. Since serotonin is associated with 
happiness and well-being, an increase in serotonin levels 
typically reduces depressive symptoms [34].
Psychotherapy involves learning cognitive and behavioral 
skills to alleviate symptoms with a mental health 
professional. If MDD-PF is severe, typically if patients 
begin harming themselves or attempt to commit suicide, 
hospitalization may be necessary. ECT is a form of 
brain stimulation therapy utilized to treat MDD-PF. 
Prevention of the initial onset of MDD may be possible. 
If a person is at risk for depression, undergoing cognitive 
or behavioral therapies may be beneficial. However, 
prevention of depression has not been studied extensively 
and is difficult to prevent due to the prominence of 
genetic factors. 
Prognosis
For both schizophrenia and MDD-PF, prognosis is 
largely dependent upon the individual. Prognosis can be 
affected by a number of factors, including the severity 
of symptoms, how early intervention begins, and genetic 
predisposition. 
Schizophrenia
The prognosis for schizophrenia is better when the 
onset of the disorder is acute and treatment begins 
early. Other factors associated with good prognosis 
include demonstrating good premorbid functioning 
and exhibiting prominent affective features [13]. If 
treatment begins late or onset is more severe, the 
prognosis is grimmer. With proper treatment, patients 
with schizophrenia can live healthy, happy lives. 
MDD-PF
Unfortunately for MDD-PF patients, the prognosis 
does not appear to be favorable; there is a high likelihood 
12.1: 29-41
Figure I: The SSRI Mechanism of Action [34]
4
The Pegasus Review: UCF Undergraduate Research Journal (URJ), Vol. 12 [2020], Iss. 1, Art. 4
https://stars.library.ucf.edu/urj/vol12/iss1/4
33www.URJ.ucf.edu
THE PEGASUS REVIEW:
UNIVERSITY OF CENTRAL FLORIDA 
UNDERGRADUATE RESEARCH JOURNAL
12.1: 29-41
of recurrence. Because of this issue, it is important that 
patients undergo long-term treatment to avoid relapse. 
According to a two-year longitudinal study, 58% of 
patients recovered while 21% had a chronic episode. The 
same study was conducted over a period of six years, in 
which 17% of patients experienced recovery and over 55% 
had chronic episodes [10]. While prognosis is dependent 
on the individual, statistical data indicates that a higher 
percentage of patients tend to experience relapse over a 
longer period of time. Prognosis is dependent on when 
treatment begins, and for treatment to be effective, it 
must be ongoing.
Psychosis
Psychosis can occur in various psychiatric disorders. 
Causes vary depending on the disorder. Traumatic life 
events and consistent marijuana usage during early 
adolescence may lead to psychosis, but some theorize that 
individuals must be genetically predisposed to develop 
these symptoms [6]. Antipsychotics can effectively 
reduce psychotic symptoms in specific disorders, but do 
not treat the underlying illness. Dopamine and glutamate 
imbalance may be crucial factors in psychotic symptoms 
[9]. 
Objective
This research aims to identify similarities between 
schizophrenia and MDD-PF. These disorders were 
chosen because they are distinct enough from each 
other that any similarities may offer significance for 
potential causes. Other psychotic symptoms share more 
similarities with schizophrenia than MDD-PF. The vast 
differences between the disorders are important because 
any shared factors may have significant implications 
for the treatment of psychotic symptoms. Ideally, we 
can observe the potential causes for psychosis when 
analyzing these disorders.
Based on existing literature, a connection between the 
disorders that can be explained by psychotic symptoms 
is plausible. A study comparing psychotic depression 
with non-psychotic depression and schizophrenia found 
that patients with MDD-PF exhibited cognitive defects 
similarly to patients with schizophrenia. This study also 
examined neuropsychological factors, such as attention 
and psychomotor speed [35]. A separate study examined 
the link between positive and negative symptoms in 
schizophrenia and MDD-PF. Results indicated that 
there was a significant correlation between positive 
psychotic symptoms and depressive symptoms in those 
with schizophrenia. This study also revealed a link 
between depressive symptoms and negative psychotic 
symptoms [36]. 
These studies amongst others indicate that there may be 
a connection between the disorders that can be explained 
by psychosis. This research examines similarities between 
the disorders to determine if a treatment could potentially 
be developed to target psychosis. We hypothesize that 
the neurological similarities between schizophrenia and 
MDD-PF will provide researchers with strategies to 
develop a treatment for psychotic symptoms.
METHODS
This research involves a meta-analysis and systematic 
literature review, in which schizophrenia and MDD-PF 
are compared to pinpoint commonalities. Five studies 
were gathered for each disorder, and three studies were 
gathered for psychosis. These studies were analyzed to 
pinpoint similarities between factors for psychosis, 
allowing us to determine whether the hypothesis would 
be rejected. We took this approach because, by combining 
data from multiple studies and by isolating data from 
previous studies, any existing biases in previous research 
can be minimized. Using this method, we can draw reliable 
conclusions. Several studies were examined individually, 
then combined to analyze the consistency of the data 
presented. We compared several factors from each study, 
including neurological similarities and pathophysiology. 
We aim to identify similarities significant enough to be 
used in the development of a treatment.
Studies
To test the hypothesis, we compared studies to determine 
whether the similarities between the disorders were 
significant. To be considered significant, the similarities 
need to offer substantial potential causes and additional 
features for psychosis. These features should show a 
reasonable amount of potential to positively influence 
the development of treatments. 
Schizophrenia 
Study 1: Neuropathology of Schizophrenia [20]
Some structural abnormalities observed in schizophrenia 
include decreased cerebral volume and widened lateral 
and third ventricles. Cerebral weight is also reduced. 
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MRI studies have indicated large reductions in brain 
volume in the temporal lobe and in medial temporal 
structures, including the hippocampus and amygdala. 
Structural imaging indicates that grey matter is more 
reduced than white matter. 
Study 2: Dopamine Hypothesis of Schizophrenia: 
Version III - The Final Common Pathway [21]
This hypothesis explores the question of whether 
symptoms in schizophrenia are related to dysfunctions 
in dopamine. Version III is the most recent version of 
this hypothesis since it accounts for the most recent 
knowledge about dopamine’s role in schizophrenia. 
This hypothesis seeks to comprehensively provide a 
framework linking risk factors to “increased presynaptic 
striatal dopaminergic function” [21]. This study 
emphasizes the environmental factors correlated with 
schizophrenia independent of genetics. Because both 
genetic and environmental factors are shown to play 
a role in dopamine dysregulation, it is thought that 
these factors work together to influence dopaminergic 
functions. 
Study 3: Molecular Genetics of Schizophrenia [27]
This study focuses on linkage studies and neurotransmitter 
response to observe the molecular genetics of 
schizophrenia. Neurotransmitters such as dopamine, 
serotonin, and glutamate have been shown to have roles 
in schizophrenia. The D3 dopamine receptor gene is 
highly concentrated in the limbic system so it may have 
a role. However, studies have been unable to confirm 
the dopamine theory. Patients with schizophrenia 
display reduced non-NDMA glutamate receptors in the 
temporal lobe and reductions in serotonin receptors in 
the PFC. 
Study 4: Prefrontal Functioning during Context 
Processing in Schizophrenia and Major Depression [29]
Patients with schizophrenia exhibit decreased cerebral 
blood flow in the prefrontal cortex, a phenomenon 
called hypofrontality. This study investigates whether 
hypofrontality occurs only in schizophrenia or if 
it manifests in other psychotic disorders. Results 
indicated that patients with schizophrenia exhibit larger 
reductions in cognition than patients with non-psychotic 
depression. It is uncertain whether dysfunctions related 
to context processing in the prefrontal cortex are specific 
to cases of schizophrenia, or if these dysfunctions appear 
in other psychiatric disorders. 
Study 5: Cognitive Impairments in Psychotic Disorders 
[18]
This study asserts that patients with schizophrenia 
experience a higher degree of impairment in cognitive 
ability compared to patients with other psychiatric 
disorders. Working and episodic memory are affected, 
partly due to the fact that the prefrontal cortex is impaired 
and has difficulty communicating with other regions of 
the brain. Schizophrenia displays a higher amount of 
cognitive impairment than affective psychosis. Results 
indicate that all psychotic disorders involve cognitive 
damage at some level. 
MDD-PF
Study 1: Clinical and Molecular Genetics [23]
This study explores the inheritance of psychotic depression 
with reference to family studies and molecular genetics. 
The dopamine beta-hydroxylase (DBH) gene is present 
at lower levels in patients with psychotic depression. This 
gene also appears to have a linkage with schizophrenia, 
as a study suggested that it may play a role in modulation 
of psychotic symptoms [37]. This linkage is separate 
from the etiology of the disorder, as researchers have 
been unable to find significant deviations in genotypic 
distribution. In a study examining the effect of DBH 
on MDD-PF, researchers concluded that the lower 
plasma DBH “was not accounted for by DBH genotype” 
[38]. The authors hypothesized that abnormal HPA 
function lowered DBH expression, which promoted 
the development of psychosis. The effects of the DBH 
gene require further study to draw any conclusions about 
its role in the development of psychotic symptoms. 
Glutamate is a neurotransmitter that may be linked 
to MDD-PF but whether the disorder is associated 
with increased or decreased glutamate concentration is 
uncertain. Serotonin receptors and transporter have not 
been associated with MDD-PF. Family studies indicate 
that psychotic depression is often inherited.
Study 2: Structural and Functional Neuroimaging 
Studies in Major Depressive Disorder with Psychotic 
Features [25]
This study focuses on the pathophysiology for psychotic 
disorders with emphasis on MDD-PF. Structural changes 
in patients with MDD-PF are observed in proportion 
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to changes in MDD without psychotic features. One 
structural change seen only in MDD-PF patients 
is a reduction in the size of the amygdala. Enlarged 
ventricles, associated with confusion and memory 
loss, and reductions in the volume of the prefrontal 
cortex were observed. MDD-PF and schizophrenia 
are structurally distinguished by a reduction in size of 
the posterior subgenual cingulate cortex (in the medial 
side of the cerebral cortex) in patients with MDD-PF. 
Further, dysfunctions in dopamine may be present in 
cases of MDD-PF, although the extent to which this 
influences the disorder is unknown [33]. 
Study 3: Cortisol Activity and Cognitive Changes in 
Psychotic Major Depression [26]
This study contends that MDD-PF is a distinct disorder 
rather than simply a subset of MDD. While this disorder 
is technically a subset of MDD, there are features that 
are not present in MDD, indicating that MDD-PF can 
be considered distinct from MDD. In this study, patients 
with MDD, patients with MDD-PF, and individuals 
without psychiatric disorders were each given a memory 
test. Memory was worse in patients with MDD-PF than 
in either other group. Studies also indicate that patients 
with MDD-PF have greater degrees of cognitive 
impairment. This definition includes problems with 
prefrontal functions and memory. 
Study 4: Hippocampal and Amygdalar Volumes in 
Psychotic and Nonpsychotic Unipolar Depression [30]
This study demonstrated that patients with MDD-
PF had much smaller amygdalar volumes. A smaller 
amygdala is often associated with reduced fear and risky 
behavior. The amygdalar volume in patients with MDD 
was shown to be similar to that of healthy subjects. There 
was no   significant difference in hippocampal volumes 
between the groups. 
Study 5: Dopaminergic Function and the Cortisol 
Response to Dexamethasone in Psychotic Depression 
[31]
This study investigated whether psychotic symptoms in 
MDD-PF could result from increased dopamine activity. 
The cortisol and hormonal responses to dexamethasone 
(DST) suppressors and activators were examined. DST, 
a drug used to treat inflammatory symptoms, has been 
observed to increase dopamine levels. The authors 
concluded that psychotic symptoms in MDD-PF do not 
appear to be related to dopamine regulation. 
Psychosis 
Study 1: Disconnection between Amygdala and Medial 
Prefrontal Cortex in Psychotic Disorders [22]
Psychotic disorders commonly impair cognitive 
functioning, including deficits in memory and reduced 
amygdalar functioning. These factors are exacerbated 
in response to distressing emotional information such 
as unemployment. When patients who suffer from 
psychotic disorders experience an emotional distractor, 
connectivity between brain regions is reduced, with 
increased reduction in volume in cases of schizophrenia. 
Study 2: Dopamine and Psychosis [24]
Studies have shown that psychosis may be triggered 
by dopamine dysfunction. This study focused on the 
links between psychosis and dopamine activity. Some 
studies suggest that psychosis is affected by factors other 
than dopamine activity such as prefrontal functioning. 
Further, additional factors occurring alongside dopamine 
dysfunction may affect the development of psychosis. 
The links between schizophrenia, psychosis, and 
dopamine were extensively researched in this study, and 
results indicate that excessive dopamine activity may 
lead to the cognitive impairments seen in schizophrenia. 
These impairments include issues with working memory, 
abstract reasoning, and other cognitive functions that 
rely on the prefrontal cortex. Based on the results of this 
study, dopamine may play a central role in the psychotic 
symptoms seen in schizophrenia and other psychotic 
disorders.
In a study examining the effects on dopamine-targeting 
therapies on schizophrenia, researchers concluded that 
antipsychotic treatments that block dopamine receptors 
show efficacy in treating positive symptoms [39]. A 
separate study found that dopamine treatments have been 
successful in treating schizophrenia, although current 
treatments mainly target the dopamine D2 receptor [40]. 
Multiple studies demonstrate the effective treatment of 
schizophrenia with therapies that target dopamine. The 
effects of dopamine-targeting therapies on MDD-PF 
have not been thoroughly studied, but these therapies 
show promise in the treatment of psychotic symptoms 
in schizophrenia. 
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Study 3: Progressive Brain Structural Changes Mapped 
as Psychosis Develops in ‘At Risk’ Individuals [28]
This study emphasizes findings indicating that 
individuals at risk for developing psychotic disorders 
display progressive structural changes in the brain prior 
to developing the disorder. Results indicate that those 
who experience psychosis demonstrate greater structural 
changes in brain structure in the prefrontal cortex than 
other regions of the brain, even before symptoms of a 
psychotic disorder develop. This finding implies that 
reductions in the volume of the prefrontal cortex may be 
associated with the development of psychosis.
RESULTS
It is important to note that patients with MDD-PF 
exhibit a reduction in size of the posterior subgenual 
cingulate cortex, while patients with schizophrenia 
do not. Because this feature is not seen in either 
schizophrenia or psychosis, it is likely the result of 
depressive features rather than psychotic features. This 
observation emphasizes that patients with MDD-PF are 
less likely to display certain psychotic features compared 
to schizophrenia, since MDD-PF has an additional 
feature (depression) not present in either schizophrenia 
or psychosis. This distinction enables effective comparison 
of certain features in order to determine whether they are 
significant.
We compared several factors, including structural 
changes and molecular backgrounds. Multiple studies 
concluded that there are changes in brain volume in 
both disorders. Specifically, it has been shown that 
amygdalar and hippocampal volumes are reduced in 
patients with schizophrenia. Patients with MDD-
PF have large reductions in amygdalar volume, but no 
significant changes in hippocampal structure. Whether 
this decrease in amygdalar volume is significant depends 
on whether psychosis is affected by structural changes 
in the amygdala. Based on existing research, a reduced 
amygdalar volume appears to be related to psychosis, 
so this factor could be considered significant. Other 
structural changes observed in both disorders include 
enlarged ventricles and reduced prefrontal cortex 
volume. Because these factors are consistent in both 
disorders, they may be considered significant for the 
hypothesis. However, to be considered significant, there 
must be additional supporting data, as these structural 
brain changes may be associated with another common 
variable.
The molecular backgrounds for each disorder include 
neurotransmitter and hormone involvement. One study 
concluded that dopamine dysregulation is not related 
to psychotic symptoms in MDD-PF. This conclusion 
contradicts the dopamine hypothesis of schizophrenia, 
which contends that dopamine dysregulation has a 
role. However, another study concluded that reduced 
concentrations of dopamine may be associated with 
MDD-PF. This study does not offer reliable evidence 
that MDD-PF is associated with decreased dopamine 
secretion, as another study concluded that the linkage 
may be insignificant or even nonexistent. This study 
indicated that dopamine dysregulation was unrelated to 
hyperactivity in the HPA axis, which was hypothesized 
to stimulate psychotic symptoms in depression. The 
hormonal responses of DST suppressors were found to 
be similar to those of non-suppressors to apomorphine 
(APO), a dopamine agonist.
Since dopamine dysfunction in MDD-PF patients 
may be unrelated to psychosis, we cannot conclude that 
dopamine directly causes psychosis. Because research 
regarding dopamine’s role in MDD-PF is limited, 
dopamine may have a larger role that has not yet been 
studied. This implication is supported by the dopamine 
hypothesis of schizophrenia, which highlights current 
evidence consistent with dopamine dysfunction playing 
a central role in psychosis. Since this is only speculation, 
the dopamine hypothesis is not significant enough 
to support our hypothesis. Other neurotransmitters 
such as serotonin and glutamate appear to have larger 
effects on one disorder compared to the other, or have 
inconsistent associations with each other. These factors 
are not sufficient supporting factors for the hypothesis. 
However, they do provide clues regarding methods 
needed to develop treatments for psychosis.
Cognitive impairments are associated with both 
disorders, although patients with schizophrenia display 
higher degrees of damage. Psychotic symptoms are 
associated with cognitive impairments similar to the 
impairments displayed in schizophrenia. Since these 
psychotic impairments are more similar to schizophrenia 
than to MDD-PF, it is difficult to say whether this factor 
could be considered significant for the hypothesis. It is 
possible that those with MDD-PF display less cognitive 
impairment because psychotic features are a “smaller 
portion” of the disorder compared to schizophrenia. 
Patients with MDD-PF often experience psychotic 
symptoms in addition to depression which set the 
disorder apart from both schizophrenia and psychosis. 
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Table 2. Molecular Structures Associated with Schizophrenia and MDD-PF
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Schizophrenia is considered almost synonymous with 
psychosis so it is expected that schizophrenia and 
psychosis would display more similar features. Because 
this possibility is hypothetical, cognitive impairment will 
not be considered a significant supporting factor. 
In terms of symptoms and epidemiology, any similarities 
would be considered insignificant, as these factors 
would not reasonably provide information needed that 
would aid in the development of treatments. The best 
treatments would target certain structural abnormalities 
in the brain, so it would not be practical to expect a 
treatment to be derived based on epidemiology and 
similar factors. Current treatments can offer insight into 
symptom management, but the development of cures is 
heavily dependent on genetic research. 
DISCUSSION
Both schizophrenia and MDD-PF appear to be affected 
by genetic and environmental factors, although the extent 
to which each disorder is affected is unknown. MDD-
PF has demonstrated a high degree of heritability so it 
is possible that the disorder is more strongly affected by 
genetics than environmental factors. Association studies 
indicate that several vulnerability genes may contribute 
to an increased risk of psychotic symptoms in depression, 
including brain derived neurotrophic factor (BDNF), 
dopamine beta-hydroxylase (DBH), and dopamine 
receptor 2 (DRD2). Additional gene variations, such 
as serotonin transporter (5-HTT) and dysbindin 
(DTNBP1) are associated with antidepressant treatment 
response in MDD-PF [6].
Hormones such as cortisol and neurotransmitters such as 
glutamate and glutamine also appear to have roles in the 
development of MDD-PF. Studies indicate that there is 
promise in targeting specific molecular markers for the 
treatment of psychotic symptoms in depression. Psychosis 
is shown to be affected by genetics and environment. 
Because of these effects, it is important to address the 
genetic and environmental risk factors for each disorder. 
Genetic similarities are more likely to offer support for 
our hypothesis, since medicinal treatments can directly 
target biological abnormalities. Environmental factors 
are better treated with psychological therapies and 
cannot be directly targeted.
Due to limitations in current research, examination of 
the similarities between these disorders is difficult. For 
example, structural abnormalities could hypothetically 
be a cause for psychosis assuming that there is no 
other common factor. It is not known whether these 
abnormalities are associated with a completely different 
aspect of each disorder. These factors provide clues for 
the structures that must be targeted, but further research 
must be conducted.
CONCLUSION
Based on the data and the lack of substantial research, the 
hypothesis for this research must be rejected. The amount 
of existing research regarding the disorders, especially 
MDD-PF, is limited. Because of this limitation, many 
similarities between MDD-PF and schizophrenia are 
speculative rather than definite. With so many gray 
areas in current research, it is difficult to pinpoint exactly 
what needs to be targeted in the treatment of psychosis. 
The hypothesis may be more strongly supported after 
substantial research is conducted. For the time being, 
there is not enough available information to draw any 
reliable conclusions regarding possible treatments.
Based on the information we gathered, there 
appears to be promise in targeting specific genes and 
neurotransmitters for the treatment of psychosis. With 
further research on psychosis, we can discover previously 
unknown factors associated with these disorders, such 
as new molecular markers. The advent of these new 
molecular markers along with a better understanding of 
the effects of anatomical features on psychotic symptoms 
could eventually lead to newer, more successful therapies 
in the future. 
12.1: 29-41
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